328 related articles for article (PubMed ID: 7904381)
1. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
[TBL] [Abstract][Full Text] [Related]
2. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
[TBL] [Abstract][Full Text] [Related]
3. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
4. KM(+), a lectin from Artocarpus integrifolia, induces IL-12 p40 production by macrophages and switches from type 2 to type 1 cell-mediated immunity against Leishmania major antigens, resulting in BALB/c mice resistance to infection.
Panunto-Castelo A; Souza MA; Roque-Barreira MC; Silva JS
Glycobiology; 2001 Dec; 11(12):1035-42. PubMed ID: 11805076
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
Scott P
J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
[TBL] [Abstract][Full Text] [Related]
9. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
Gurunathan S; Prussin C; Sacks DL; Seder RA
Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.
Noormohammadi AH; Hochrein H; Curtis JM; Baldwin TM; Handman E
Vaccine; 2001 Jul; 19(28-29):4043-52. PubMed ID: 11427281
[TBL] [Abstract][Full Text] [Related]
11. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
12. Beryllium, an adjuvant that promotes gamma interferon production.
Lee JY; Atochina O; King B; Taylor L; Elloso M; Scott P; Rossman MD
Infect Immun; 2000 Jul; 68(7):4032-9. PubMed ID: 10858219
[TBL] [Abstract][Full Text] [Related]
13. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
[TBL] [Abstract][Full Text] [Related]
15. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
Stober CB; Lange UG; Roberts MT; Alcami A; Blackwell JM
J Immunol; 2005 Aug; 175(4):2517-24. PubMed ID: 16081824
[TBL] [Abstract][Full Text] [Related]
16. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice.
Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Rafati S
Parasite Immunol; 2011 Jun; 33(6):335-48. PubMed ID: 21410716
[TBL] [Abstract][Full Text] [Related]
17. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.
Aebischer T; Wolfram M; Patzer SI; Ilg T; Wiese M; Overath P
Infect Immun; 2000 Mar; 68(3):1328-36. PubMed ID: 10678945
[TBL] [Abstract][Full Text] [Related]
18. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.
Sjölander A; Baldwin TM; Curtis JM; Bengtsson KL; Handman E
Vaccine; 1998 Dec; 16(20):2077-84. PubMed ID: 9796067
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
